Seralutinib NDA submitted to FDA for pulmonary arterial hypertension

Sponsor

Gossamer Bio $GOSS

Drug

seralutinib

Indication

Pulmonary arterial hypertension

Gossamer Bio files a new drug application with the FDA for seralutinib in pulmonary arterial hypertension; no filing acceptance or action date disclosed.